New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
10:39 EDTWAG, VRTX, TV, CP, OHRP, BVN, CVC, MEOH, ENRHigh option volume stocks
High option volume stocks: TV ENR BVN VRTX MEOH OHRP WAG ASHR CVC CP
News For TV;ENR;BVN;VRTX;MEOH;OHRP;WAG;CVC;CP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 13, 2015
07:19 EDTVRTXVertex shares should have upward momentum in near-term, says JMP Securities
Subscribe for More Information
May 12, 2015
19:37 EDTCVCCablevision to pull out of Daily News auction, Reuters says
Subscribe for More Information
17:54 EDTVRTXOn The Fly: After Hours Movers
Subscribe for More Information
16:49 EDTVRTXVertex resumes after-hours trading, shares up 5.6% to $131.00
Subscribe for More Information
16:20 EDTVRTXVertex to resume trading at 14:45
16:19 EDTVRTXVertex confirms FDA panel voted 12-to-1 to recommend approval of Orkambi
Subscribe for More Information
16:16 EDTVRTXVertex confirms FDA panel voted 12-to-1 to recommend approval of Orkambi
16:16 EDTVRTXPiper Jaffray remains confident in approval for Vertex
Subscribe for More Information
15:43 EDTVRTXFDA panel votes 12 to 1 that data supports Orkambi approval
Subscribe for More Information
15:35 EDTVRTXFDA panel votes unanimously that data support Orkambi safety
Subscribe for More Information
15:32 EDTVRTXFDA panel inconclusive on if Lumacaftor contributes to Orkambi effectiveness
Subscribe for More Information
10:23 EDTVRTXVertex shares halted while FDA panel meeting takes place
07:58 EDTVRTXFDA Pulmonary-Allergy Drugs Advisory Committee to hold a meeting
Subscribe for More Information
May 11, 2015
16:14 EDTOHRPOhr Pharmaceutical reports Q2 net loss ($3.4M) vs.($2M) in Q214
Subscribe for More Information
07:40 EDTVRTXFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertexís Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasnít announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
May 8, 2015
14:13 EDTVRTXOrkambi questions may make reimbursement talks harder, says Evercore ISI
Subscribe for More Information
14:10 EDTMEOHMethanex to host investor meeting
Subscribe for More Information
10:10 EDTVRTXPiper confident in Vertex getting positive panel vote for Orkambi
Piper Jaffray said the briefing documents posted for next Tuesday's advisory committee meeting on Vertex's Orkambi combo drug did not raise any new or surprise safety concerns and that the efficacy concerns raised do not "hold much water" when compared to the unmet clinic benefit of the drug. The firm said it remains confident in a positive panel vote and approval of the drug by the May 5 PDUFA date and reiterate kits Overweight rating and $146 price target on Vertex shares.
09:28 EDTVRTXOn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTVRTXFDA staff question if Vertex CF drug combo adds benefit over ivacaftor alone
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use